Diltiazem attenuates oxidative stress in diabetic rats

Renal Failure

Volumn 27, Issue 3, 2005, Pages 335-344

  Anjaneyulu, Muragundla ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Diabetic nephropathy; Diltiazem; Lipidperoxidation; Nitric oxide; Oxidative stress; Streptozotocin

Indexed keywords

CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CATALASE; CREATININE; DILTIAZEM; GLUTATHIONE; MALONALDEHYDE; NITRIC OXIDE; NITROGEN; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; CALCIUM CELL LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; CATALASE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DILTIAZEM; FOLLOW-UP STUDIES; GLUTATHIONE; KIDNEY; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; NITRITES; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 20044390236     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200056630     Document Type: Article

References (49)

1. Ibrahim, H.N.; Hostetter, T.H. Diabetic nephropathy. J. Am. Soc. Nephrol. 1997, 8, 487-493.
2. Ziyadeh, F.N. The extracellular matrix in diabetic nephropathy. Am. J. Kidney Dis. 1993, 22, 736-744.
3. Ha, H.; Kim, K.H. Role of oxidative stress in the development of diabetic nephropathy. Kidney Int. 1995, 48 (Suppl. 51), S18-S21.
4. Larkins, R.G.; Dunlop, M.E. The link between hyperglycemia and diabetic nephropathy. Diabetologia 1992, 35, 499-504.
5. Ruiz, C.; Alegria, A.; Barbera, R.; Farre, R.; Lagarda, M.J. Lipid peroxidation and antioxidant enzyme activities in patients with type-I diabetes mellitus. Scand. J. Clin. Lab. Invest. 1994, 59, 99-105.
6. Ruiz-Munoz, L.M.; Vidai-Vanacloch, F.; Lampreabe, I. Enalapril inhibits hydrogen-peroxide production by murine mesangial cells exposed to high glucose concentration. Nephrol. Dial. Transplant. 1997, 12, 456-464.
7. Ha, H.; Lee, S.H.; Kim, K.H. Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, lipid peroxidation induced y high glucose in cultured mesangial cells. J. Pharm. Exp. Ther. 1997, 28, 1462-1497.
8. Hunt, J.V.; Bottoms, M.A.; Mitchinson, M.J. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation: some fundamental differences in proposed mechanism of glucose oxidation and oxidant production. Biochem. J. 1993, 291, 259-262.
9. Baynes, J.W. Role of oxidative stress in development of complication in diabetes. Diabetes 1991, 40, 405-412.
10. Cooper, M.E. Interaction of metabolic and homodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44, 1957-1972.
11. Kasiske, B.L.; O'Donnell, M.P.; Keane, W.F. Renal effects of angiotensin II: modulation by calcium and cyclooxygenase products. Am. J. Physiol. 1986, 251 (20), F1043-F1048.
12. Mene, P.; Simonson, M.S.; Dunn, M.J. Physiology of the mesangial cell. Physiol. Rev. 1989, 69, 1347-1424.
13. Parving, H.H.; Lehnert, H.; Brochner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345, 870-878.
14. Wolf, G.; Ziyadesh, F.N. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am. J. Kidney Dis. 1997, 29, 153-163.
15. Yavuz, D.; Kucukkaya, B.; Haklar, G.; Ersoz, O.; Akoglu, E.; Akalin, S. Effects of captopril and losartan on lipid peroxidation, protein oxidation and nitric oxide release in diabetic rat kidney. Prostaglandins Leukot. Essent Fatty Acids 2003, 69, 223-227.
16. Elena, M.V.; de, Cavanagh; Inserra, F.; Toblli, J.; Stella, I.; Fraga, C.G.; Ferder, L. Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001, 38, 1130-1136.
17. Anjaneyulu, M.; Chopra, K. Effect of irbesartan on the antioxidant defense system and nitric oxide release in diabetic rat kidney. Am. J. Nephrol. 2004a, 24 (5), 488-496.
18. Gaber, L.; Walton, C.; Brown, S.; Bakris, G. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 1994, 46, 161-169.
19. Brown, S.A.; Walton, C.L.; Crawford, P.; Bakris, G.L. Long-term effects of antihypertensive regimens on renal hemodynamic and proteinuria. Kidney Int. 1993, 43, 1210-1218.
20. Luno, J.; Garcia, D.E.; Vinuesa, S.; Gomez-Campdera, F.; Lorenzo, I.; Valderrabano, F. Effects of antihypertensive therapy on progression of diabetic nephropathy. Kidney Int. 1998, 68 (Suppl.), S112-S119.
21. Baba, T.; Murabayshi, S.; Takabe, K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonists in hypertension type 2 diabetic patients with microalbuminuria: a randomized controlled trial. Diabetologia 1989, 32, 40-44.
22. Bakris, G.L.; Copley, J.B.; Vicknair, N.; Sadler, R.; Leurgans, S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996, 50, 1641-1650.
23. Anjaneyulu, M.; Chopra, K. Nordihydroguairetic acid, a lignin, prevents oxidative stress and the development of diabetic nephropathy in rats. Pharmacology 2004b, 72, 42-50.
24. Kedziora-kornatowska, K.; Szram, S.; Kornatowski, T.; Szadujkis-Szadurski, L.; Kedziora, J.; Bartosz, G. The effect of verapamil on the antioxidant defense system in diabetic kidney. Clin. Chim. Acta 2002, 322, 105-112.
25. Schmidt, F.H. Methodon der harn-und blutzuckerbestrimmung II: Handbuch Des. Diabetes Mellitus 1971, 2, 938.
26. Anjaneyulu, M.; Ramarao, P. Studies on gastrointestinal tract functional changes in diabetic animals. Methods Find Exp. Clin. Pharmacol. 2002, 2, 71-75.
27. Wills, E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 1996, 99, 667-676.
28. Owens, L.; Belcher, R.V. A colorimetric micromethod for the determination of glutathione. Biochem. J. 1965, 94, 75-79.
29. Kono, Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophy. 1978, 186, 189-195.
30. Luck, H. Catalase. Methods of Enzymatic Analysis; Bergmeyer, H.U., Ed.; Academic Press: New York, 1971; 885-893.
31. Lowry, O.H.; Rosen-Brough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin-Phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
32. Raghvendra, V.; Agrewala, J.N.; Kulkarni, S.K. Melatonin reversal of lipopolysaccharide-induced thermal and behavioral hyperalgesia in mice. Eur. J. Pharmacol. 2000, 395, 15-21.
33. Adler, A.I.; Stratton, I.M.; Neil, H.A.; Yudkin, J.S.; Matthews, D.R.; Cull, C.A.; Wright, A.D.; Turner, R.C.; Holman, R.R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J. 2000, 321, 412-419.
34. Salahudeen, A.K.; Kanji, V.; Reckelhoff, J.F.; Schmidt, A.M. Pathogenesis of diabetic nephropathy: a radical approach. Nephrol. Dial. Transplant. 1997, 12, 664-668.
35. Anjaneyulu, M.; Chopra, K. Quercetin, an antioxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin. Exp. Pharmacol. Physiol. 2004c, 31, 244-248.
36. Trachtman, H.; Futterweit, S.; Bienkowski, R.S. Taurine prevents glucose-induced lipidperoxidation and increased collagen production in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 1993, 199, 759-765.
37. Padi, S.S.; Chopra, K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 2002, 92 (3), 685-692.
38. Sugimoto, K.; Tsuruoka, S.; Fujimura, A. Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. Clin. Exp. Pharmacol. Physiol. 2001, 28, 829-830.
39. Murali, B.; Goyal, R.K. Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. Clin. Exp. Hypertens. 2001, 23, 513-520.
40. Kakkar, R.; Mantha, S.V.; Radhi, J.; Prasad, K.; Kalra, J. Antioxidant defense system in diabetic kidney: a time course study. Life Sci. 1997, 60, 667-679.
41. Sukalski, K.A.; Pinto, K.A.; Berntson, J.L. Decreased susceptibility of liver mitochondria from diabetic rats to oxidative damage and associated increase in alpha-tocopherol. Free Radic. Biol. Med. 1993, 14, 57-65.
42. Arai, K.; Iizuka, S.; Tada, Y.; Oikawa, K.; Taniguchi, N. Increase in the glucosylated form of erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glycosylation with the enzyme activity. Biochim. Biophys. Acta 1987, 19, 292-296.
43. Mene, P. Calcium channel blockers: what they can and what they can not do. Nephrol. Dial. Transplant. 1997, 12, 25-28.
44. Rodicio, J.L.; Campo, C.; Ruilope, L.M. Renal effects of calcium antagonists. Nephrol. Dial. Transplant. 1995, 10 (Suppl. 9), 17-22.
45. Tikkanen, I.; Johnston, C.L. Comparison of renin-angiotensin to calcium channel blockade in renal disease. Kidney Int. 1997, 52 (Suppl. 63), S19-S22.
46. Paller, M.S.; Hoidal, J.R.; Ferris, T.E. Oxygen free radicals in ischemia acute reanl failure in the rats. J. Clin. Invest. 1984, 72, 1156-1164.
47. Craven, P.A.; De Rubertis, F.R.; Melhem, M. Nitric oxide in diabetic nephropathy. Kidney Int. 1997, 52 (Suppl. 60), S46-S53.
48. Pieper, G.M. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine supplementation. Hypertension 1998, 31, 1047-1060.
49. Onozato, M.L.; Tojo, A.; Goto, A.; Fujita, T.; Wilcox, C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effect of ACEI and ARB. Kidney Int. 2002, 61, 186-194.